Circulating adiponectin concentrations are reduced in obese individuals, and this reduction
has been proposed to have a crucial role in the pathogenesis of atherosclerosis and …

Cardiovascular disease is the leading cause of morbidity and mortality in diabetes. Recent
clinical studies indicate that sodium-glucose co-transporter 2 (SGLT2) inhibitors improve …

Metabolic-dysfunction-associated steatotic liver disease (MASLD) is a chronic liver disease
that affects more than a quarter of the global population and whose prevalence is increasing …

Sodium–glucose linked transporter type 2 (SGLT2) inhibitors are a relatively new class of
antidiabetic drugs with positive cardiovascular and kidney effects. The aim of this review is to …

Objective In recent years, some authoritative clinical studies have found that SGLT2 inhibitor
can reduce cardiovascular risk in patients with diabetes, which may imply that SGLT2 …

Sodium glucose cotransporter 2 inhibitors (SGLT2i) block the reabsorption of glucose by
inhibiting SGLT2, thus improving glucose control by promoting the renal excretion of …

Diabetes is a leading cause of morbidity and mortality worldwide. Management of diabetes
is changing at a rapid pace. Three new classes of antidiabetic drugs including GLP-1 …

Background: Sodium-glucose cotransporter 2 inhibitors (SGLT2i) are a novel category of
oral antidiabetic drugs that inhibit renal glucose reabsorption and increase renal glucose …

The glucagon-like peptide-1 receptor agonist (GLP-1RA) dulaglutide has been shown to
improve body weight and glycemic control and reduce major cardiovascular (CV) events. In …

Background/Objectives: The health burden of metabolic dysfunction-associated fatty liver
disease (MASLD) has been increasing lately. Cardiovascular disease (CVD) is the main …